Excess catecholamine syndrome: prevention and therapy

Diabetes mellitus type-2

incidence +33% since 1990

persons in their 30s: +70%

health care expenditure: more than cancer

preceded by insulin resistance

Hypertension

often associated with diabetes

incidence approx. 25%

if treated yet higher mortality

Associated metabolic disorders

hypertriglyceridemia

hyperuricemia

The site focusses on links between lifestyle, sympathetic overactivity and cardiovascular disease. Therapeutics are described which counteract sympathetic overactivity by reducing catecholamine release: the centrally acting imidazoline I1 receptor agonist moxonidine and the angiotensin receptor blocker (ARB) eprosartan with a high presynaptic inhibitory action on norepinephrine release.

Since eprosartan has a unique structure, i.e. the first non-tetrazol and non-biphenyl ARB, it differs from other ARBs by inhibiting more potently presynaptic norepinephrine release. Eprosartan controls high blood pressure by a "dual mechanism of action". Based on this dual mechanism of action, the "Teveten Song - The Power of Two" has been composed and presented by the singers Ogie and Janno on occasion of the Teveten Launch in Manila, May 27, 2003.

An overview on the EXCESS CATECHOLAMINE SYNDROME can be downloaded as PDF.
An update focuses on "Addominal fat and sympathetic overactivity - from calorie intake to postmenopausal hypertension"

Please read this important disclaimer


		Help